TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/09/26	NT$12.60	+0.80%	77,508
04/09/26	NT$12.50	-1.96%	70,005
03/09/26	NT$12.75	+0.39%	93,044
02/09/26	NT$12.70	-1.55%	20,054
01/09/26	NT$12.90	0.00%	4,017

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 07/09/2026			5-day change	1st Jan Change
12.60 ^TWD	+0.80%		-2.33%	-42.47%

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.41B 44.77M 38.51M 36.22M 33.06M 61.83M 4.23B 62.03M 429M 166M 2.17B 168M 164M 6.91B	P/E 2024	-20.5x	P/E 2025	-11x
Enterprise Value	1.08B 34.3M 29.5M 27.75M 25.33M 47.37M 3.24B 47.52M 329M 127M 1.66B 129M 126M 5.29B	EV / Sales 2024	286x	EV / Sales 2025	75.1x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/09/25	TaiRx, Inc.(TPEX:6580) dropped from S&P Global BMI Index	CI
14/08/25	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/04/25	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23/09/24	TaiRx, Inc.(TPEX:6580) added to S&P Global BMI Index	CI
11/08/24	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/04/24	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
09/08/23	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
11/04/23	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/08/22	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
13/04/22	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
09/08/21	Tairx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	CI

1 day	+0.80%
1 week	-2.33%
Current month	-2.33%
1 month	-4.91%
3 months	-17.11%
6 months	-29.21%
Current year	-42.47%

TaiRx, Inc. Stock

Stocks

6580

TW0006580004

Biotechnology & Medical Research

Valuation : TaiRx, Inc.

Chart: TaiRx, Inc.

Latest news : TaiRx, Inc.

Press Releases : TaiRx, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : TaiRx, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	12.35	12.8
1 month	12.2	13.8
Current year	11.95	23.45
1 year	11.95	31.8
3 years	11.95	44
5 years	11.95	89.5
10 years	11.95	89.5

Manager	Title	Age	Since
Yi Wen Chu IRC	Investor Relations Contact	-	-
Du Shieng Chien CEO	Chief Executive Officer	-	22/08/2011
Jackson Huang DFI	Director of Finance/CFO	-	05/10/2015

Director	Title	Age	Since
Du Shieng Chien CHM	Chairman	-	22/08/2011
Yi Wen Chu BRD	Director/Board Member	-	18/12/2013
Hsiu Hui Li BRD	Director/Board Member	-	22/08/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TAIRX, INC.	+0.80%	-2.33%	-48.78%	-54.84%	44.77M
LONZA GROUP AG	+0.05%	-2.32%	-1.02%	+16.66%	48.41B
REVOLUTION MEDICINES, INC.	-0.40%	+2.16%	+418.57%	+554.47%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.52%	+42.67%	+22.27%	44.07B
BEONE MEDICINES AG	-1.22%	-0.37%	+4.82%	+84.42%	40.73B
CELLTRION, INC.	-0.96%	-1.38%	+15.75%	+45.91%	33.21B
ASCENDIS PHARMA A/S	-0.21%	+2.86%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-0.45%	+21.42%	+117.63%	16.5B
EUROFINS SCIENTIFIC SE	-0.81%	-0.75%	+11.11%	+31.08%	14.45B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	+0.09%	+75.93%	+41.15%	13.77B
Average	-0.62%	+0.03%	+60.05%	+95.42%	27.4B
Weighted average by Cap.	-0.74%	-0.02%	+89.57%	+135.30%

	2024	2025
Net sales	8.22M 261K 224K 211K 192K 360K 24.64M 361K 2.5M 966K 12.62M 979K 957K 40.2M	27.88M 883K 760K 715K 652K 1.22M 83.55M 1.22M 8.47M 3.28M 42.79M 3.32M 3.25M 136M
Net income	-139M -4.4M -3.78M -3.56M -3.25M -6.08M -416M -6.1M -42.2M -16.31M -213M -16.52M -16.16M -679M	-221M -7.01M -6.03M -5.67M -5.17M -9.68M -663M -9.71M -67.21M -25.98M -339M -26.32M -25.74M -1.08B
Net Debt	-505M -16M -13.76M -12.94M -11.81M -22.1M -1.51B -22.17M -153M -59.32M -775M -60.09M -58.78M -2.47B	-330M -10.47M -9.01M -8.47M -7.73M -14.46M -990M -14.51M -100M -38.82M -507M -39.32M -38.46M -1.62B